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Correspondence Efficacy and Safety of Dabigatran Compared
to Warfarin in Patients With Paroxysmal,
Persistent, and Permanent Atrial Fibrillation
Results From the RE-LY (Randomized Evaluation
of Long-Term Anticoagulation Therapy) StudyTo the Editor: Dabigatran etexilate 150 mg twice daily (bid) is more
effective than warfarin for prevention of stroke and systemic embolism
in patients with atrial fibrillation (AF) with no increase in major
bleeding (1). Dabigatran etexilate 110 mg bid reduces major bleeding
compared to warfarin with similar efficacy. In this analysis, the effect
of 2 doses of dabigatran etexilate was compared to warfarin in patients
with paroxysmal, persistent, and permanent AF.
A total of 5,943 patients with paroxysmal AF, 5,789 with persis-
tent AF, and 6,375 with permanent AF were included in this analysis
from the RE-LY (Randomized Evaluation of Long-Term Anticoag-
ulation Therapy) study, which randomly assigned patients with AF
and risk factors for stroke to either warfarin or dabigatran, 150 mg bid
or 110 mg bid. The classification of the type of AF was made solely
by the enrolling physician at the time of study entry.
Compared to patients with persistent AF, patients with paroxysmal
AF weighed less, had a lower CHADS2 score, were less often male,
ad a shorter duration of AF, were less likely to have a previous
ardioversion, were less likely to have heart failure, were more likely to
ave hypertension, and were less likely to have received a vitamin K
ntagonist (VKA). At baseline, they were more likely to receive
spirin, beta-blockers, calcium-channel blockers, amiodarone, or st-
tins, and were less likely to receive an angiotensin-receptor blocker
ARB), an angiotensin-converting enzyme (ACE) inhibitor, or
igoxin. Compared to patients with permanent AF, patients with
aroxysmal AF weighed less, had a lower CHADS2 score, were less
often male, had a shorter duration of AF, were less likely to have heart
failure but more likely to have coronary artery disease (CAD), were
more likely to have hypertension, and were less likely to have received
a VKA. They were more likely to receive aspirin, beta-blockers,
calcium-channel blockers, amiodarone, and statins, but less likely to
receive an ARB, an ACE inhibitor, or digoxin. Compared to patients
with permanent AF, patients with persistent AF weighed more, were
less often male, had shorter duration of AF, were more likely to have
a previous cardioversion, were less likely to have heart failure, were
more likely to have CAD, and were less likely to have received a VKA.
At baseline, they were more likely to receive aspirin, calcium-channel
blockers, amiodarone, or statins, but less likely to receive an ARB, an
ACE inhibitor, beta-blockers, or digoxin.
The time in the therapeutic range for patients with paroxysmal,
persistent, and permanent AF was 63.9%, 63.4%, and 65.8% respec-
tively. After a mean follow-up of 2 years, the overall risk of stroke or
systemic embolism in patients with paroxysmal, persistent, and
permanent AF were similar, with rates of 1.32%, 1.55%, and 1.49%
per year, respectively. The overall risk of major bleeding in patientswith paroxysmal, persistent, and permanent AF was 3.57%, 3.29%,
and 2.92% per year, respectively (Fig. 1).
Dabigatran etexilate 150 mg bid was more effective than
warfarin for stroke and systemic emboli in paroxysmal AF (hazard
ratio [HR]: 0.61, 95% confidence interval [CI]: 0.42 to 0.90), in
persistent AF (HR: 0.64, 95% CI: 0.43 to 0.93), and in permanent
AF (HR: 0.70, 95% CI: 0.48 to 1.01). The p value for interaction
was 0.8335. Dabigatran etexilate 110 mg bid was comparable to
warfarin for the prevention of stroke or systemic embolism in
persistent AF (HR: 0.96, 95% CI: 0.69 to 1.35) and in permanent
AF (HR: 1.13, 95% CI: 0.81 to 1.57) and had a favorable point
estimate in paroxysmal AF (HR: 0.60, 95% CI: 0.41 to 0.89). The
p value for interaction was 0.0465 (Fig. 1). For stroke and systemic
embolism, this analysis has a power of 80% to detect an
interaction between type of AF by treatment above a relative
difference of 65%.
The effects of both doses of dabigatran etexilate versus warfarin
on major bleeding were consistent. Dabigatran etexilate 150 mg
bid was similar to warfarin in paroxysmal AF (HR: 0.96, 95% CI:
0.77 to 1.21), in persistent AF (HR: 0.81, 95% CI: 0.64 to 1.03),
and in permanent AF (HR: 1.04, 95% CI: 0.82 to 1.33). The p
value for interaction was 0.3421. Dabigatran 110 mg bid reduced
major bleeding compared to warfarin, with similar point estimates
in paroxysmal AF (HR: 0.78, 95% CI: 0.61 to 0.99), persistent AF
(HR: 0.74, 95% CI: 0.57 to 0.94), and permanent AF (HR: 0.92,
95% CI: 0.71 to 1.18). The p value for interaction was 0.4367
(Fig. 1). For major bleeding, this analysis has a power of 80% to
detect an interaction between type of AF by treatment above a
relative difference of 40%.
For stroke or systemic embolism, mean peak and trough levels were
not significantly different between either dose of dabigatran etexilate
for patients with paroxysmal, persistent, and permanent AF.
In this analysis, dabigatran etexilate 150 mg bid, compared to
warfarin, provided superior efficacy for stroke prevention with com-
parable major bleeding risks, consistent with the main RE-LY study
results. Dabigatran etexilate 110 mg bid, compared to warfarin,
provided a comparable reduction in stroke and systemic emboli in
persistent and permanent AF, with a point estimate that was appar-
ently better than expected for the reduction of these events in
paroxysmal AF. The reasons for these differences in efficacy are
uncertain. There was no significant interaction present when all 3
treatment groups were evaluated simultaneously. There was no
interaction in the dabigatran 150 mg bid dose compared to warfarin.
There is no biologically plausible explanation for this effect, and the
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February 28, 2012:854–6peak and trough values did not differ significantly among the 3 groups
of patients. Because of these reasons and because there was no prior
hypothesis that dabigatran 110 mg bid would have this effect, we
conclude that these results may be due to a play of chance.
In summary, the benefits of dabigatran etexilate compared to
warfarin on efficacy and safety were similar in patients with
permanent, persistent, and intermittent AF.
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Figure 1 Event Rates and Hazard Ratios
Shown are the rates of stroke and systemic embolism and the rates of major blee
(W) for the different types of atrial fibrillation (AF). The hazard ratios with 95% con
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